OCR aims to accelerate the development of new human and pet treatments for serious chronic diseases
by addressing the unmet need of providing access to highly predictive models via ethical clinical studies in pets. OCR works with pharmaceutical partners – Human health – for the cost-effective design and management of clinical trials in dogs and cats with spontaneous diseases, as well as in vitro/ex-vivo studies. This innovative approach helps to advance the R&D process for new drug candidates and medical devices for humans in a variety of therapeutic areas including oncology, cardiology, neurology and inflammation. OCR has already signed partnerships with leading players in the veterinary sectors for pilot & pivotal clinical studies in Pets.
